Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weight-Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer-Associated VTE
NCT03297359Phase 2Terminated
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Mar 2018
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of dalteparin in venous thromboembolism (VTE), sponsored by Ottawa Hospital Research Institute. Started Mar 2018; status: terminated.
02
Drugs
dalteparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03297359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03297359.